Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors

By              

Oncology Reports, Vol. 27, Iss. 6, 2012-01 ,pp. : 1794-1800

Spandidos Publications

Access to resources Recommend Favorite

Molecular mechanisms of lungspecific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors (Review)

By Sakao Seiichiro   Tatsumi Koichiro  

Oncology Letters, Vol. 4, Iss. 5, 2012-11 ,pp. : 865-867

Spandidos Publications

Access to resources Recommend Favorite

Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action (Review)

By Xu Yaping   Sheng Liming   Mao Weimin  

Oncology Letters, Vol. 5, Iss. 1, 2013-01 ,pp. : 19-24

Spandidos Publications

Access to resources Recommend Favorite

Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

By Ayoola Ayodele   Barochia Amit   Belani Kiran   Belani Chandra P.  

Cancer Investigation, Vol. 30, Iss. 5, 2012-05 ,pp. : 433-446

Informa Healthcare

Access to resources Recommend Favorite

Biological Characteristics and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Efficacy of EGFR Mutation and its Subtypes in Lung Adenocarcinoma

By Lu Rong-li   Hu Cheng-Ping   Yang Hua-ping   Li Yuan-yuan   Gu Qi-hua   Wu Lielin  

Pathology & Oncology Research, Vol. 20, Iss. 2, 2014-04 ,pp. : 445-451

Springer Publishing Company

Access to resources Recommend Favorite